Current and Long- Term Liabilities (Tables)

3 Months Ended

Mar. 31, 2018

Payables and Accruals [Abstract]

Schedule of accrued expenses

Accrued expenses consisted of the following as of March 31, 2018 and December 31, 2017 (in thousands):

	March 31, 2018		December 31, 2017
Commercial rebates, fees and returns	$	114,884	$	102,357
Professional, license, and other fees and expenses	29,033		28,692
Salaries, bonuses, and other compensation	14,034		19,099
Interest expense	6,639		13,525
Bremelanotide milestone payment	20,000		—
Intrarosa-related license fees	10,000		10,000
Accrued research and development	4,481		1,817
Total accrued expenses	$	199,071	$	175,490